Loading…
CRISPR Therapeutics AG is projected to rise to $59.53 by 2027, a +12% move from its current price of $53.35. CRSP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $51.76 | $53.37 | $55.03 | +0.04% |
| Jul 14 | $51.12 | $53.39 | $55.76 | +0.08% |
| Jul 15 | $50.65 | $53.41 | $56.33 | +0.12% |
| Jul 16 | $50.25 | $53.43 | $56.81 | +0.15% |
| Jul 17 | $49.91 | $53.45 | $57.25 | +0.19% |
| Jul 18 | $49.60 | $53.47 | $57.65 | +0.23% |
| Jul 19 | $49.32 | $53.49 | $58.02 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $49.32 | $53.49 | $58.02 | +0.27% |
| Week 2 | $47.82 | $53.64 | $60.17 | +0.54% |
| Week 3 | $46.73 | $53.79 | $61.90 | +0.82% |
| Week 4 | $45.85 | $53.93 | $63.44 | +1.09% |
| Week 5 | $45.10 | $54.08 | $64.84 | +1.36% |
| Week 6 | $44.45 | $54.22 | $66.15 | +1.64% |
| Week 7 | $43.86 | $54.37 | $67.40 | +1.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CRISPR Therapeutics AG is a gene editing company focused on developing gene-based medicines for serious human diseases using its CRISPR/Cas9 platform. Its portfolio spans therapies for hemoglobinopathies, CAR T cell approaches, in vivo programs, and type 1 diabetes, with a lead ex vivo cell therapy candidate called CASGEVY designed to treat transfusion-dependent beta-thalassemia, severe sickle cell disease, and related hemoglobinopathies by editing hematopoietic cells to produce high levels of fetal hemoglobin in red blood cells. The company also advances CAR T programs, including CTX112 targeting CD19 and CTX131 targeting CD70, along with in vivo programs CTX310 and CTX320, and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for type 1 diabetes.
CRISPR Therapeutics has strategic partnerships with Vertex Pharmaceuticals Incorporated and was incorporated in 2013, with headquarters in Zug, Switzerland.
Categorized in Healthcare, CRISPR Therapeutics operates at the intersection of gene editing and medicine, pursuing a portfolio across multiple disease areas and therapeutic modalities. The description emphasizes a focus on gene-based medicines and a broad development pipeline alongside strategic industry collaborations and a European corporate base.
CRISPR Therapeutics AG (CRSP) is a Healthcare stock trading at $56.34 with a market cap of $5.55B. It is ranked 1308 by market capitalization. The asset sits within the Healthcare sector and is positioned in the gene editing space with a portfolio spanning hemoglobinopathies, CAR T approaches, and in vivo programs.
The current price sits in a context of a longer-run upside, with multi-year forecasts indicating a path of rising averages from 2026 onward and potential gains by 2030 and beyond. The long-run outlook highlights meaningful upside, though forecasts are estimates and carry inherent uncertainty.
Forecasts show the average price advancing from 2026 onward, with a 2030 avg of $103.33 and a 2050 avg of $418.31, and with max forecasts reaching $152.75 by 2030 and $796.48 by 2050. Across years, the max values and the associated ROIs rise significantly, ending with a 642.5% ROI in 2050 while sentiment remains bullish in the later years.
A major floor 20.4% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 16.0% above — a clean break opens room to run.
A major ceiling 26.2% above — clearing it would confirm fresh momentum.
Key CRSP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRSP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $58.31 | Sell | $56.62 | Sell |
| MA 10 | $57.31 | Sell | $56.71 | Sell |
| MA 20 | $55.04 | Sell | $55.68 | Sell |
| MA 50 | $53.29 | Buy | $54.09 | Sell |
| MA 100 | $52.95 | Buy | $53.62 | Sell |
| MA 200 | $55.49 | Sell | $53.45 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.94 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -45.08 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -1.19 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.36 | Buy |
| Awesome (5,34) | 4.24 | Buy |
| Ultimate (7,14,28) | 46.92 | Neutral |
| Momentum (10) | -0.63 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 57.27 | Sell |
| ADX (14) | 14.12 | Neutral |
| ATR (14) | 1.67 | Info |
The 30-day technical picture shows a cautiously constructive setup with a neutral-to-bullish tilt. The RSI(14) sits at 50, and near-term moving averages show the SMA50 at $53.26 and the SMA200 at $55.53, guiding near-term price behavior.
Support is identified at $49.44 and resistance at $61.89, framing a 30-day range of $46.38 to $68.44. These levels imply a window for price action over the next month, with volatility a notable factor given the 60% annualized volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $44.34 | $53.35 | $71.26 | 0% | Neutral | |
| $46.85 | $59.53 | $80.35 | +12% | Neutral | |
| $51.54 | $67.60 | $95.04 | +27% | Bullish | |
| $64.65 | $87.08 | $126.39 | +63% | Bullish | |
| $68.35 | $94.23 | $140.47 | +77% | Bullish | |
| $65.66 | $92.49 | $141.12 | +73% | Bullish | |
| $69.78 | $100.27 | $156.21 | +88% | Bullish | |
| $68.86 | $100.82 | $160.06 | +89% | Bullish | |
| $75.76 | $112.93 | $182.40 | +112% | Bullish | |
| $93.52 | $141.81 | $232.75 | +166% | Bullish | |
| $104.78 | $171.86 | $301.59 | +222% | Bullish | |
| $190.89 | $359.12 | $694.38 | +573% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $44.34 | $53.35 | $64.41 | +0.00% |
| August 2026 | $47.03 | $55.68 | $67.84 | +4.37% |
| September 2026 | $46.30 | $55.27 | $68.17 | -0.75% |
| October 2026 | $45.15 | $54.25 | $67.62 | -1.84% |
| November 2026 | $46.00 | $55.60 | $69.92 | +2.49% |
| December 2026 | $46.27 | $56.22 | $71.26 | +1.11% |
Click any year to see its month-by-month CRSP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
CRISPR Therapeutics AG's 2026 outlook centres on $53.35, within a $44.34 to $71.26 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CRSP could reach as high as $80.35, with a base case around $59.53 and support toward $46.85 — roughly +12% from $53.35. Price action looks broadly range-bound.
Expect CRSP to range from $51.54 to $95.04 through 2028. The $67.60 average target implies a +27% move from current prices. That is up +14% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CRSP price prediction for 2029 points to an average of $87.08 (low $64.65, high $126.39) — a potential gain of +63% on today's $53.35. Momentum favours further upside here.
In 2030, CRSP is projected to trade between $68.35 and $140.47, averaging $94.23 — a potential gain of +77% from today's $53.35. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
CRISPR Therapeutics AG's 2031 outlook centres on $92.49, within a $65.66 to $141.12 range. That is -2% versus the projected 2030 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2032, CRSP could reach as high as $156.21, with a base case around $100.27 and support toward $69.78 — roughly +88% from $53.35. Buyers look set to stay in control over this stretch.
Expect CRSP to range from $68.86 to $160.06 through 2033. The $100.82 average target implies a +89% move from current prices. That is up +1% on the projected 2032 average. Momentum favours further upside here.
The CRSP price prediction for 2034 points to an average of $112.93 (low $75.76, high $182.40) — a potential gain of +112% on today's $53.35. Buyers look set to stay in control over this stretch.
In 2035, CRSP is projected to trade between $93.52 and $232.75, averaging $141.81 — a potential gain of +166% from today's $53.35. That is up +26% on the projected 2034 average. Momentum favours further upside here.
CRISPR Therapeutics AG's 2040 outlook centres on $171.86, within a $104.78 to $301.59 range. That is up +21% on the projected 2035 average. That marks a +222% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CRSP could reach as high as $694.38, with a base case around $359.12 and support toward $190.89 — roughly +573% from $53.35. Momentum favours further upside here.
Investing $1,000 in CRSP today (≈ 18.744142 CRSP) could be worth
$6,731.38
+$5,731.38 (+573%) by 2050 · US Dollar
Based on the average projected CRSP price of $359.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRSPwould be worth at today's price.
$1,000 invested in CRSP on Jul 10, 2025 (≈ 16.949153 CRSP) would be worth
$904.24
-$95.76 (-9.6%) today · 0.90× · US Dollar
Based on a CRSP entry price of $59 vs. today's $53.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $60.08 | $887.98 | -11.2% |
| 1 month ago | $49.44 | $1,079.09 | +7.9% |
| 3 months ago | $51.22 | $1,041.59 | +4.2% |
| 6 months ago | $55.3 | $964.74 | -3.5% |
| 1 year ago | $59 | $904.24 | -9.6% |
| All time (5.0y) ago | $135.55 | $393.58 | -60.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRSP forecast.
Our base-case forecast reaches $110.00 around 2034.
Implied market cap at $110.00: $10.83B
Over the multi-year horizon, the forecast sequence depicts substantial upside for CRSP. In 2030, the min is $75.51, the avg is $103.33, and the max is $152.75, with an ROI of 83.4%. These figures illustrate meaningful appreciation potential while highlighting the variability across the year.
The 2040 forecast shows the min $124.08, the avg $200.24, and the max $346.87, with an ROI of 255.4%. This point underscores a further acceleration in expected price movement and returns.
By 2050, the min stands at $227.76, the avg at $418.31, and the max at $796.48, with an ROI of 642.5%. The sentiment across these later years is bullish, reflecting a strong long-term growth narrative, though these figures are not guarantees and carry substantial uncertainty in biotech valuations.
Overall, the forecast series suggests rising price levels and expanding ROIs through 2030, 2040, and 2050, with higher upside potential accompanied by typical biotech investment risks such as execution, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
2030 forecast values are min $75.51, avg $103.33, max $152.75 with an ROI of 83.4% and bullish sentiment.
Forecasts show positive ROIs across multiple years (e.g., 13.9% in 2027, 32% in 2028, 68.9% in 2029, 83.4% in 2030, 642.5% in 2050) with bullish sentiment in later years, but these figures are estimates and not guarantees.
Yes. The 2040 forecast lists an avg of $200.24 and a max of $346.87, with a 255.4% ROI; min is $124.08, and sentiment is bullish.
The 30-day range is $46.38-$68.44, RSI(14) is 50, SMA50 is $53.26, SMA200 is $55.53, with support at $49.44 and resistance at $61.89. Annualized volatility is 60%.
Current price is $56.34 and market cap is $5.55B, with a rank of 1308.
CRISPR Therapeutics AG Community Discussion
0Share your CRISPR Therapeutics AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.